首页> 外文期刊>Chemistry: A European journal >A Divalent PAMAM-Based Matrix Metalloproteinase/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome
【24h】

A Divalent PAMAM-Based Matrix Metalloproteinase/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome

机译:基于二价PAMAM的基质金属蛋白酶/碳酸酐酶抑制剂治疗干眼症

获取原文
获取原文并翻译 | 示例
           

摘要

Synthetic sulfonamide derivatives are a class of potent matrix metalloproteinase inhibitors (MMPI) that have potential for the treatment of diseases related to uncontrolled expression of these enzymes. The lack of selectivity of the large majority of such inhibitors, leading to the inhibition of MMPs in tissues other than the targeted one, has dramatically reduced the therapeutic interest in MMPIs. The recent development of efficient drug delivery systems that allow the transportation of a selected drug to its site of action has opened the way to new perspectives in the use of MMPIs. Here, a PAMAM-based divalent dendron with two sulfonamidic residues was synthesized. This nanomolar inhibitor binds to the catalytic domain of two MMPs as well as to the transmembrane human carbonic anhydrases (hCAs) XII, which is present in the eye and considered an antiglaucoma target. In the animal model of an experimental dry eye, no occurrence of dotted staining in eyes treated with our inhibitor was observed, indicating no symptoms of corneal desiccation.
机译:合成磺酰胺衍生物是一类有效的基质金属蛋白酶抑制剂(MMPI),具有治疗与这些酶表达不受控制有关的疾病的潜力。绝大多数此类抑制剂缺乏选择性,导致除了靶向药物以外的其他组织中的MMPs受到抑制,大大降低了对MMPIs的治疗兴趣。有效药物输送系统的最新发展允许将选定的药物输送到其作用部位,这为使用MMPI的新观点开辟了道路。在此,合成了具有两个磺酰胺基残基的基于PAMAM的二价树枝状分子。这种纳摩尔抑制剂与两个MMP的催化结构域以及跨膜人碳酸酐酶(hCAs)XII结合,后者存在于眼睛中,被认为是抗青光眼的靶标。在实验性干眼症的动物模型中,在用我们的抑制剂治疗的眼睛中未观察到斑点染色的出现,这表明没有角膜干燥的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号